iMedicor Receives Statement of Work from Franklyn Ideas

Statement of Work Authorizes iMedicor to Provide Marketing Services to one of
Franklyn`s Key Clients
NANUET, N.Y.--(Business Wire)--
iMedicor (OTCBB: VMCI) today announced it has received a Scope of Work (SOW)
order from its partner, Franklyn Ideas, LLC (Franklyn) on behalf of one of its
major pharmaceutical clients. The project calls for the direct marketing of
pharma products via iMedicor`s HIPAA-compliant portal utilizing a proprietary
system that will allow the client to target specific physician groups in their
marketing efforts.

This SOW is the first of many such projects envisioned by the two companies when
they executed a Strategic Alliance Agreement disclosed in Vemics` Form 10-K
filed on October 13, 2009.
http://www.sec.gov/Archives/edgar/data/1408057/000118518509001039/vemics-10k63009.htm
The project is expected to launch by January 2010.

"We are extremely pleased that our combined efforts this year have resulted in
iMedicor`s deployment of this innovative approach to on-line pharmaceutical
marketing with one of Franklyn Ideas key clients," said Fred Zolla, CEO of
iMedicor. "Our technology will allow their client to market directly to highly
profiled medical practices and healthcare providers, and we look forward to
using our success with this launch to build other relationships with Franklyn
Ideas."

"iMedicor represents a disruptive approach for reaching a distinct, targeted
market with specific messages" said Stacey Richter, President and Founder of
Franklyn Ideas, "We are excited about the potential this new approach represents
for our client base."

iMedicor has recently announced Transgenomic and Access Pharmaceutical companies
as early adopters of its marketing service. This SOW represents the first in
what is expected to be several additional clients and users of the iMedicor
Pharma Marketing Platform over the next six months.

About iMedicor:

iMedicor is the only HIPAA-compliant solution for interoperable medical
information transfer that is offered at no cost to healthcare providers and
patients. The iMedicor portal also enables pharmaceutical companies to deliver
customized marketing programs to more than 730,000 healthcare providers
nationwide in a highly targeted, cost-effective and non-intrusive manner; allows
doctors, administrators and other qualified healthcare workers to send and
receive medical records, files and images; and enables disparate EMR (electronic
medical record) systems to communicate, collaborate and exchange records in real
time. More information on iMedicor is available at www.imedicor.com.

The statements contained herein, other than historical information, are or may
be deemed to be forward-looking statements and involve factors, risks, and
uncertainties that may cause actual results in future periods to differ
materially from such statements. These factors, risks, and uncertainties include
market acceptance of iMedicor`s products and services; the nonexclusive and
terminable-at-will nature of certain of the company's partnerships and
agreements; rapid technological change affecting demand for our products and
services; competition from companies providing similar products and services,
availability of sufficient financial resources to enable us to expand our
operations, as well as other risks detailed from time to time in our filing s
with the Securities and Exchange Commission.

iMedicor
Investor:
Craig Stout, 845-356-5211
Chief Operating Officer
cstout@imedicor.com
or
Media:
Aimee Whitelaw, 202-997-1114
Communications Adviser
awhitelaw@imedicor.com

Copyright Business Wire 2009